Skip to content

Electrical stimulation of the subthalamic nucleus for the treatment of focal motor seizures

Electrical stimulation of the subthalamic nucleus for the treatment of focal motor epileptic seizures

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000034018
Enrollment
Unknown
Registered
2020-06-21
Start date
2020-06-18
Completion date
Unknown
Last updated
2020-08-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Epilepsy

Interventions

experimental group:phase I: electrical stimulation of the subthalamic nucleus (3v)
phase II: electrical stimulation (0v)
control group:phase I: electrical stimulation (0v)
phase II: electrical stimulation of the subthalamic nucleus (3v)

Sponsors

Xuanwu Hospital of Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18-60 years; 2. diagnosed as refractory epilepsy (resistant to AED medication for at least 2 years); 3. epileptogenic zone located in the motor or supplementary motor area; 4. with difficuty in resection surgery or refusal of resection surgery; 5. agree to participate into this study and sign on the informed consent form; 6. comply with the protocol of this study and agree on the follow-up examination as requested.

Exclusion criteria

Exclusion criteria: 1. with brain tumors or degenerative disorders of CNS; 2. with psychiatric disorders, cannot cooperate in the related examinations; 3. with morphological lesions in the subthalamic nucleus; 4. severe cognitive dysfunction, IQ < 50; 5. genetic generalized epilepsy or special inherited epilepsy; 6. pregnant women or those with high risk of hemorrhage; 7. other severe diseases and disorders, those with severe liver or lung dysfunction; 8. cannot undergo electrical stimulation due to objective causes; 9. abnormal results of laboratory examination in the screeing period, or those with significant clinical implications.

Design outcomes

Primary

MeasureTime frame
seizure frequency;seizure severity;quality of life;

Secondary

MeasureTime frame
cognitive functions;

Countries

China

Contacts

Public ContactTao Yu

Beijing Institute of Functional Neurosurgery, Xuanwu Hospital of Capital Medical University

yutaoly@sina.com+86 13391769290

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026